ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 395.65 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 289.02K shares.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 106.63K shares.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 71.92K shares.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 156.48K shares.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 645.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 289.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 395.65K shares 10-Q · filed 2026-08-13 | 467.58K shares derived: sum of 3 quarters · filed 2026-08-13 | 624.05K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 106.63K shares 10-Q · filed 2026-05-15 | 178.56K shares derived: sum of 2 quarters · filed 2026-05-15 | 335.04K shares derived: sum of 3 quarters · filed 2026-05-15 | |
| 2025-12-31 | 71.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 228.40K shares derived: sum of 2 quarters · filed 2026-03-09 | 645.55K shares 10-K · filed 2026-03-09 | |
| 2025-09-30 | 156.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 573.63K shares 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 417.15K shares 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |